These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 3360112)

  • 21. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathogenetic features of coronary heart disease combined with chronic obstructive pulmonary diseases and efficiency of therapy with trimetazidin].
    Kolomoets NM; Baksheev VI; Uvaĭsova KU
    Klin Med (Mosk); 2008; 86(6):38-43. PubMed ID: 18720710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
    Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.
    Nayak VK; Desai NK; Kshirsagar NA; Bhandarkar SD; Satoskar RS
    J Postgrad Med; 1991 Jan; 37(1):5-8. PubMed ID: 1941694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
    Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB
    Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
    Chen M; Xu D; Hu XL; Wang H
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetic characteristics of drug substance in liver denervation].
    Ashirmetov AKh; Krakovskiĭ ME
    Farmakol Toksikol; 1989; 52(1):77-80. PubMed ID: 2707429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical and experimental research on the drug-metabolizing function of the liver in peritonitis].
    Khakimov ZZ; Nadzhimutdinov KN; Akhmedov RM
    Farmakol Toksikol; 1988; 51(2):80-2. PubMed ID: 3378613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of verapamil on the functional state of the liver in ischemic heart disease].
    Zharov EI; Makeeva LG; Svetova SD; Makarovskiĭ VV; Shafranskiĭ IuA; Vertkina NV
    Sov Med; 1991; (12):10-3. PubMed ID: 1780769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of estrogens on pharmacokinetics of phenazone and N-acetyl-p-aminophenol].
    Kwiatkowski A
    Ann Acad Med Stetin; 1991; 37():35-47. PubMed ID: 1816754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term administration of verapamil in coronary disease].
    Tkaczewski W; Goch JH; Bala T; Kuklewicz C
    Pol Tyg Lek; 1977 Oct; 32(44):1719-21. PubMed ID: 917918
    [No Abstract]   [Full Text] [Related]  

  • 33. [Indirect method of determining drug-metabolizing enzyme activity and its clinical application].
    Nedel'kina SV; Dianova II; Subbotina RS; Salganik RI
    Vopr Med Khim; 1977; (6):844-7. PubMed ID: 595490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Detoxification function of the liver and body resistance in patients with acute intestinal obstruction].
    Razzakov SM; Krakovskiĭ ME; Ashirmetov AKh
    Khirurgiia (Mosk); 1990 Dec; (12):11-5. PubMed ID: 2079783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat conductivity and skin temperature at the treatment of ischemic heart disease with curantyl and isoptin.
    Kollár J; Uhrík J; Hejj F
    Int Angiol; 1991; 10(1):34-7. PubMed ID: 2071972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of age on the pharmacokinetics of verapamil.
    Ahmed JH; Meredith PA; Elliott HL
    Pharmacol Res; 1991 Oct; 24(3):227-33. PubMed ID: 1956867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged half-life of verapamil in a case of overdose: implications for therapy.
    Buckley CD; Aronson JK
    Br J Clin Pharmacol; 1995 Jun; 39(6):680-3. PubMed ID: 7654488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease.
    Husum D; Johnsen A; Jensen G
    Pharmacol Toxicol; 1990 Mar; 66(3):163-9. PubMed ID: 2333271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction to: "PBPK Modeling to Unravel Nonlinear Pharmacokinetics of Verapamil to Estimate the Fractional Clearance for Verapamil N-Demethylation in the Recirculating Rat Liver Preparation".
    Drug Metab Dispos; 2015 Jul; 43(7):1060. PubMed ID: 26015561
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy].
    Rumiantsev DO; Piotrovskiĭ VK; Metelitsa VI; Riabokon' OS; Kokurina EV
    Farmakol Toksikol; 1988; 51(1):66-70. PubMed ID: 3360112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.